Fate Therapeutics Inc
(STU:F6T)
€
2.915
0.144 (5.2%)
Market Cap: 332.29 Mil
Enterprise Value: 147.14 Mil
PE Ratio: 0
PB Ratio: 0.92
GF Score: 66/100 Fate Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 14, 2023 / 07:05PM GMT
Release Date Price:
€4.98
(+0.84%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everyone and welcome to Barclays Global Healthcare Conference. We're in Miami, and do raise your hand or e-mail us if you have questions. My name is Peter Lawson. I'm one of the mid-cap biotech analyst at Barclays, focusing on oncology, really delighted to have up on stage with me, the CEO from Fate, Scott Wolchko.
Questions & Answers
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst
And I guess the first question is really kind of I guess, opponent from most people is just kind of J&J collaboration kind of how that unfolded if you can kind of shed any more light around...
J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director
Sure -- I mean I'll do as best as I can with it. It certainly is a bit of a surprise. We were making a lot of progress under the J&J collaboration. Headed into the fourth quarter, J&J had already exercised a commercial
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot